Peer-influenced content. Sources you trust. No registration required. This is HCN.

ACP HospitalistCefepime-induced Neurotoxicity

An elderly patient exhibited signs of cognitive disarray, which emerged three days subsequent to a hospital discharge following osteomyelitis treatment.


An elderly man’s confusion post-osteomyelitis treatment prompts an exploration into the potential neurotoxic effects of cefepime, a frequently used fourth-generation cephalosporin, especially in patients with renal dysfunction.

Key Points:

  • The patient was an 87-year-old male who presented confusion and decreased responsiveness three days after being discharged from an osteomyelitis treatment involving IV cefepime.
  • Despite not having cefepime levels obtained, the improvement of the patient’s mental status after the antibiotic change to ertapenem indicated cefepime-induced neurotoxicity.
  • Cefepime-induced neurotoxicity can occur in up to 0.15% of all patients and 15% of ICU patients, with symptoms typically delayed by a median of four days from treatment initiation.
  • One primary risk factor for cefepime-induced neurotoxicity is renal dysfunction which increases the unbound, active form of cefepime in the blood.

Additional Points:

  • Cefepime neurotoxicity mechanism involves the competitive inhibition of the γ-aminobutyric acid (GABA) receptor, which can lower the seizure threshold and lead to encephalopathy.
  • The blood-brain barrier can be disrupted by renal dysfunction, sepsis, uremia, or prior central nervous system infection, allowing for greater penetration of cefepime, from 10% in normal conditions up to 45%.
  • Cefepime toxicity treatment includes stopping the offending agent, managing seizure activity with antiepileptics, and in some cases, initiating hemodialysis.

Conclusion:

  • The connection between cefepime and neurotoxicity, especially in patients with renal impairment, emphasizes the importance of monitoring cefepime levels in high-risk patients.

Nephrology Latest Posts

Did You Know?
Neurotoxicity affects up to 15% of people over the age of 60, with polypharmacy and pre-existing neurological and renal conditions significantly increasing the risk.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form